SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
SAb Biotherapeutics (Nasdaq: SABS) will present clinical and translational data for its lead program SAB-142 at the 51st ISPAD Annual Conference in Montréal, Nov 5–8, 2025.
Six presentations (four oral, two posters) describe Phase 1 results showing a multi-specific mechanism of action with sustained immunomodulation, a favorable safety profile at target dose without serum sickness or anti-drug antibodies, and a novel pharmacokinetic assay for measuring SAB-142.
The presentations cover specimen quality methods, binding specificity profiling, immunomodulation without sustained lymphodepletion, mechanism of action, PK assay details, and safety findings, led by SAB BIO scientific and clinical leaders.
SAb Biotherapeutics (Nasdaq: SABS) presenterà dati clinici e traslazionali per il suo programma principale SAB-142 durante la 51ª conferenza annuale ISPAD a Montréal, dal 5 all'8 novembre 2025.
Sei presentazioni (quattro orali, due poster) descrivono i risultati della fase 1 che mostrano un meccanismo d'azione multi-specifico con immunomodulazione sostenuta, un profilo di sicurezza favorevole alla dose bersaglio senza sieroproteina o anticorpi anti-farmaco, e un nuovo saggio farmacocinetico per misurare SAB-142.
Le presentazioni coprono metodologie di qualità dei campioni, profilazione della specificità di legame, immunomodulazione senza deplezione linfocitaria sostenuta, meccanismo d'azione, dettagli del saggio PK e risultati di sicurezza, guidate dai leader scientifici e clinici di SAB BIO.
SAb Biotherapeutics (Nasdaq: SABS) presentará datos clínicos y traslacionales para su programa principal SAB-142 en la 51.ª Conferencia Anual ISPAD en Montreal, del 5 al 8 de noviembre de 2025.
Seis presentaciones (cuatro orales, dos pósteres) describen resultados de la Fase 1 que muestran un mecanismo de acción multi-específico con modulación inmunitaria sostenida, un perfil de seguridad favorable a la dosis objetivo sin fiebre del suero ni anticuerpos anti-fármaco, y un nuevo ensayo farmacocinético para medir SAB-142.
Las presentaciones cubren métodos de calidad de las muestras, perfil de especificidad de unión, inmunomodulación sin depleción linfocitaria sostenida, mecanismo de acción, detalles del ensayo PK y hallazgos de seguridad, dirigidas por líderes científicos y clínicos de SAB BIO.
SAb Biotherapeutics (나스닥: SABS)은 몬트리올에서 열리는 제51회 ISPAD 연차 학술대회에서 주력 프로그램 SAB-142에 대한 임상 및 전이 데이터를 발표할 예정입니다. 2025년 11월 5–8일.
여섯 개의 발표(네 편의 구두 발표, 두 편의 포스터)가 1상 결과를 설명하며 다중 표적 작용 기전과 지속된 면역 조절, 목표 용량에서의 유리한 안전성 프로파일을 보여주고, 혈청병이나 약물 항체 없이 SAB-142를 측정하기 위한 새로운 약물동태 검사를 제공합니다.
발표는 시료 품질 방법, 결합 특이성 프로파일링, 지속된 림프구 고갈 없이의 면역조절, 작용 기전, PK 검사 세부사항 및 안전성 소견 등을 SAB BIO의 과학 및 임상 리더들이 이끕니다.
SAb Biotherapeutics (Nasdaq: SABS) présentera des données cliniques et translationnelles pour son programme phare SAB-142 lors de la 51e Conférence annuelle ISPAD à Montréal, du 5 au 8 novembre 2025.
Six présentations (quatre orales, deux affiches) décrivent les résultats de la phase 1 montrant un mécanisme d'action multi-spécifique avec une immunomodulation soutenue, un profil de sécurité favorable à la dose ciblée sans maladie du sérum ni anticorps anti-médicament, et un nouvel essai pharmacocinétique pour mesurer SAB-142.
Les présentations couvrent les méthodes de qualité des échantillons, le profilage de la spécificité de liaison, l'immunomodulation sans déplétion lymphocytaire soutenue, le mécanisme d'action, les détails de l'essai PK et les résultats de sécurité, dirigés par les responsables scientifiques et cliniques de SAB BIO.
SAb Biotherapeutics (Nasdaq: SABS) wird klinische und translational Daten für ihr führendes Programm SAB-142 auf der 51. ISPAD-Jahreskonferenz in Montréal vom 5. bis 8. November 2025 vorstellen.
Sechs Präsentationen (vier mündliche, zwei Poster) beschreiben Ergebnisse der Phase 1, die einen multi-spezifischen Wirkmechanismus mit anhaltender Immunmodulation zeigen, ein günstiges Sicherheitsprofil bei der Ziel-Dosis ohne Serumkrankheit oder Antidrug-Antikörper, und einen neuen pharmakokinetischen Test zur Messung von SAB-142.
Die Präsentationen decken Methoden zur Probenqualität, Bindungsspezifizität, Immunmodulation ohne anhaltende Lymphozytendepression, Wirkmechanismus, PK-Testdetails und Sicherheitsbefunde ab, geleitet von führenden wissenschaftlichen und klinischen Leitern von SAB BIO.
SAb Biotherapeutics (بورصة ناسداك: SABS) ستعرض بيانات سريرية ونقلية لبرنامجها الرائد SAB-142 في المؤتمر السنوي الحادي والخمسين لـ ISPAD في مونتريال، من 5 إلى 8 نوفمبر 2025.
ستقدم ست عروض (أربعة شفوية، واثنان ملصقان) نتائج المرحلة الأولى التي تُظهر آلية عمل متعددة الأهداف مع تنظيم مناعي مستمر، و< b>ملف أمان واعد عند الجرعة المستهدفة بدون مرض فرط التحسس الدموي المصلي أو أجسام مضادة مضادة للأدوية، واختبار فارماكوكينيتكي جديد لقياس SAB-142.
تشمل العروض طرق جودة العينة، وتحديد خصوصية الارتباط، والتعديل المناعي بدون استنفاد لمناعة الغدد اللمفاوية بشكل مستمر، وآلية العمل، وتفاصيل اختبار PK، ونتائج السلامة، بقيادة القادة العلميين والسريريين في SAB BIO.
- None.
- None.
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that four oral presentations and two poster presentations have been accepted for presentation at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD) being held November 5-8, 2025 in Montréal, Canada. Data highlights the progress of SAB BIO’s lead program, SAB-142, which is in development for delaying the progression of T1D in new onset Stage 3 patients.
Key data to be presented includes:
- Data from the Phase 1 study showcasing the clinically validated, multi-specific mechanism of action with sustained immunomodulation of SAB-142.
- Safety data from the Phase 1 trial of SAB-142 demonstrating a favorable safety profile, characterized as not causing serum sickness or anti-drug antibodies at target dose.
- Details of the novel pharmacokinetic assay for measuring SAB-142.
“We are making significant progress with the development of SAB-142, and the data we are sharing at this year’s ISPAD annual conference adds to the supporting body of evidence for SAB-142 as a potential best-in-class therapy for the treatment of Stage 3 autoimmune type 1 diabetes,” said presenting author Christoph Bausch, Chief Operating Officer, SAB BIO.
Oral Presentation Details:
Title: Specimen quality for multicenter clinical trials: comparing novel blood preservation methods to cryopreserved PBMC
Session: Oral Session II: Genes, cells and pathways | Presentation 12
Presenter: Eric Sandhurst, PhD, Director, Program Management, SAB BIO
Presentation Date & Time: Wednesday, November 5, 2025 | 4:38 – 4:46 p.m. ET
Location: Session Hall 3
Title: Profiling the Binding Specificities of SAB-142, a Fully Human Anti-Thymocyte Globulin, Against T Cell Surface Proteins
Session: Oral Session V: Treatment in diabetes | Presentation 42
Presenter: Diane Maher, PhD, Director, Program Management, SAB BIO
Presentation Date & Time: Friday, November 7, 2025 | 11:38 – 11:46 p.m. ET
Location: Session Hall 3
Title: Immunomodulation Without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin
Session: Oral Session V: Treatment in diabetes | Presentation 43
Presenter: Stan Stoyanov, MD, Vice President, Clinical Development, SAB BIO
Presentation Date & Time: Friday, November 7, 2025 | 11:46 – 11:54 p.m. ET
Location: Session Hall 3
Title: Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment of Type 1 Diabetes
Session: Oral Session V: Treatment in diabetes | Presentation 44
Presenter: Christoph Bausch, PhD, Chief Operating Officer, SAB BIO
Presentation Date & Time: Friday, November 7, 2025 | 11:54 a.m. – 12:02 p.m. ET
Location: Session Hall 3
Poster Presentation Details:
Title: Novel Pharmacokinetic (PK) Assay for Measuring SAB-142, a Fully Human Anti-Thymocyte Globulin
Session: Poster Corner 4: Novel Advances and Interventions; Diabetes in Developing Countries and Migrant Populations | Presentation 123
Presenter: Evan Gardner, Senior Manager, Clinical Bioanalysis, SAB BIO
Presentation Date & Time: Thursday, November 6, 2025 | 3:15 – 4:15 p.m. ET
Location: Exhibition & Poster Area
Title: Safety Profile of SAB-142: a Fully Human Anti-Thymocyte Globulin
Session: Poster Corner 2: New insulins; Adjunctive Therapies; Other Pharmacologic Agents; Novel Advances and Interventions
Presenter: Stan Stoyanov, MD, Vice President, Clinical Development, SAB BIO
Presentation Date & Time: Friday, November 7, 2025 | 3:15 – 4:15 p.m. ET
Location: Exhibition & Poster Area
About SAB-142
SAB-142 is a potentially disease-modifying, re-dosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes (T1D). SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) with a mechanism of action analogous to that of rabbit ATG (rATG). rATG has demonstrated in multiple clinical trials the ability to slow disease progression in patients with new or recent onset of Stage 3 T1D. SAB-142, like rATG, directly targets multiple immune cells involved in destroying pancreatic beta cells, including modulation of “bad acting” T-lymphocytes like Cytotoxic T-cells. By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells.
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary platform which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. For more information, visit www.sab.bio.
Forward-Looking Statements
Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the development and clinical trial results of the Company’s T1D program and other discovery programs.
These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
CONTACTS
Investor Relations:
Cristi Barnett
ir@sab.bio
Media:
Sheila Carlson
media@sab.bio
FAQ
What data will SABS present at ISPAD Nov 5–8, 2025 regarding SAB-142?
Does the SABS Phase 1 data report safety concerns like serum sickness or anti-drug antibodies?
How many SABS presentations are scheduled at ISPAD 2025 and what formats are they?
Which SAB-142 topics will be covered in the oral sessions by SABS at ISPAD Nov 7, 2025?
Who are the SABS presenters for the SAB-142 data at ISPAD 2025?
Where and when can investors view the SAB-142 poster on the novel PK assay?
